Chasing Shadows: The Untold Stories of Corporate Crime and Collapse

In 2014, Theranos told its investors it made one hundred million dollars in revenue. The real number was one hundred thousand. Last week, we talked about chasing the shadows where corporate crime hides—today, we’re dragging one of the biggest frauds of the 21st century directly into the light. This is the story of a company once valued at nine billion dollars, built on a single drop of blood… and a sea of lies. The story starts with a name: Elizabeth Holmes. A nineteen-year-old Stanford dropout with a compelling vision. She wanted to revolutionize healthcare.

No more big needles. No more waiting for lab results. Just a tiny fingerprick, a small box called the Edison, and a complete health profile in minutes. It was a beautiful idea. It was also a fantasy. Holmes raised over seven hundred million dollars from investors. She packed her board with powerful old men—George Shultz, Henry Kissinger—who lent her credibility she hadn't earned. They saw the next Steve Jobs. They bought the black turtleneck. They bought the deep, affected voice. They bought the nine-billion-dollar valuation. But inside the walls of Theranos, the engineers knew the truth.

The Edison machine didn't work. It produced wild, inaccurate results. So what did the company do? They cheated. When doctors and patients sent in blood samples, Theranos employees would secretly run them on standard, commercially available machines from companies like Siemens. They just weren't telling anyone. The entire operation was a charade. Holmes and her second-in-command, Sunny Balwani, ruled through fear and secrecy. They demanded absolute loyalty. The incentive was simple: keep the story alive. Because the story was the only thing keeping the money flowing.

The moment the story died, the company died. So they lied to investors. They lied to partners like Walgreens. And they lied to patients about the reliability of their tests. Then, an investigative journalist got a tip. John Carreyrou at The Wall Street Journal started asking questions. He found sources—brave employees willing to break their non-disclosure agreements. Theranos fought back. Hard. They hired David Boies, one of the most feared lawyers in America, to intimidate and threaten Carreyrou’s sources. They put immense pressure on the Journal's owner, Rupert Murdoch—who was also a Theranos investor—to kill the story.

For a moment, it looked like they might succeed. But in October 2015, the bombshell article dropped. The fantasy world shattered. The fallout was swift. Regulators shut down their labs. Walgreens pulled out. The SEC charged Holmes and Balwani with massive fraud. The company that promised to change the world laid off hundreds of employees. But here’s the part of the story that often gets missed. Who benefits from a collapse? In December 2017, with the company bleeding cash, a hedge fund called Fortress Investment Group loaned Theranos one hundred million dollars.

The terms were predatory. Fortress knew Theranos would default. And when it did, Fortress took control of the company’s only real asset: its patents. All one thousand, one hundred and seventy-five of them. Fortress got them for pennies on the dollar. They can now sell them, license them, or sue other biotech companies for infringement. Holmes lost. The employees lost. The investors lost. But the firm that showed up to pick at the bones… they walked away with the intellectual property, ready to monetize the wreckage.